1. Home
  2. NUS vs ACIU Comparison

NUS vs ACIU Comparison

Compare NUS & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nu Skin Enterprises Inc.

NUS

Nu Skin Enterprises Inc.

HOLD

Current Price

$4.65

Market Cap

222.9M

Sector

Health Care

ML Signal

HOLD

Logo AC Immune SA

ACIU

AC Immune SA

HOLD

Current Price

$2.83

Market Cap

247.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUS
ACIU
Founded
1984
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Other Pharmaceuticals
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
222.9M
247.6M
IPO Year
1996
2015

Fundamental Metrics

Financial Performance
Metric
NUS
ACIU
Price
$4.65
$2.83
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
429.5K
128.3K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
3.36%
N/A
EPS Growth
207.80
N/A
EPS
N/A
N/A
Revenue
$3,176,718,000.00
N/A
Revenue This Year
N/A
$706.75
Revenue Next Year
$7.14
$321.13
P/E Ratio
N/A
N/A
Revenue Growth
48.98
N/A
52 Week Low
$4.49
$2.10
52 Week High
$12.59
$4.00

Technical Indicators

Market Signals
Indicator
NUS
ACIU
Relative Strength Index (RSI) 50.16 N/A
Support Level $4.52 N/A
Resistance Level $4.96 N/A
Average True Range (ATR) 0.16 0.00
MACD 0.02 0.00
Stochastic Oscillator 62.22 0.00

Price Performance

Historical Comparison
NUS
ACIU

About NUS Nu Skin Enterprises Inc.

Nu Skin Enterprises Inc develops and distributes a comprehensive line of beauty and wellness solutions in various countries. The company operates in two primary product categories: beauty and wellness products. Additionally, the company also operates through its subsidiary, Rhyz. It reports revenue from nine segments, consisting of its seven geographic Nu Skin segments: Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan and two Rhyz segments: manufacturing, which includes manufacturing and packaging subsidiaries it has acquired; and Rhyz Other, which includes other investments by its Rhyz strategic investment arm. The majority of the company's revenue is generated from the Wellness product category from the Americas segment.

About ACIU AC Immune SA

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: